Mira Pharmaceuticals Reports Preclinical Data of Ketamir-2 to Treat Depression

Share this
Mira Pharmaceuticals

Mira Pharmaceuticals Reports Preclinical Data of Ketamir-2 to Treat Depression


  • MIRA has reported preclinical data from the safety & efficacy study of Ketamir-2 vs traditional ketamine to treat depression & treatment-resistant depression (TRD) in male mice. The IND submission to the US FDA is anticipated in H2'24
  • Results depicted a dose-related increase in locomotor activity & travel speed with a trend favoring higher time spent in the arena center. Increased travel distance & speed were also seen with mice spending greater time in open arms of the maze, indicating reduced anxiety
  • Ketamir-2 further decreased swimming distances & speed, suggesting less behavioral despair & antidepressant effect, as well as immobility times. Traditional ketamine was inactive when administered at the highest dose possible

Ref: MIRA Pharmaceuticals | Image: MIRA Pharmaceuticals

Related News:- MIRA Pharmaceuticals & MIRALOGX Entered into an Exclusive Licensing Agreement for Ketamir-2

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions